Financial Highlights
Consolidated results under International Financial Reporting Standards (IFRS) for the quarter ended December 31, 2012
- Revenues were `10,424 crore for the quarter ended December 31, 2012;
QoQ growth was 5.7%
YoY growth was 12.1%
- Revenues excluding Lodestone were `10,210 crore;
QoQ growth was 3.6%
YoY growth was 9.8%
- Net profit after tax was `2,369 crore for the quarter ended December 31, 2012, which remained unchanged compared to the quarter ended September 30, 2012
- Earnings per share (EPS) was `41.47 for the quarter ended December 31, 2012against `41.46 for the quarter ended September 30, 2012
- Liquid assets including cash and cash equivalents, current available-for-sale financial assets, investment in certificates of deposits and government bonds were`22,501crore versus `22,570crore as on September 30, 2012.
Other highlights:
- The company won 8 large outsourcing deals amounting to US$ 731 million of total contract value
- 14new wins for Infosys' products and platforms
- Infosys and its subsidiaries added 53 clients during the quarter
- Gross addition of 7,499employees (net addition of 977) for the quarter by Infosys and its subsidiaries.
- 1,55,629 employees as on December 31, 2012 for Infosys and its subsidiaries
- Completed the acquisition of Lodestone Holding AG, a leading management consultancy based in Switzerland
- Infosys American Depositary Shares (ADS) have started trading on the New York Stock Exchange (NYSE) under the ticker symbol 'INFY'. The company is in the process of listing its ADS on the Paris and London exchanges of NYSE Euronext.
“We have done well in this quarter despite an uncertain environment,” said S. D. Shibulal, CEO and Managing Director.“We continue to gain confidence from a strong pipeline of large deals. However, the broader economic environment remains difficult. Even so, we remain cautiously optimistic about the January-March quarter”, he added.
“We were able to maintain our margins through efficiency improvements despite increased operating expenses. We remain focused on making the right investments for profitable and sustainable growth in the longer term", said Rajiv Bansal, Chief Financial Officer.
Outlook*
The company's outlook (consolidated) for the fiscal year ending March 31, 2013, under IFRS is as follows:
- Revenues**are expected to be atleast `40,746crore;
- Earnings per share (EPS) is expected to beatleast `162.80;
* Conversion 1 US$ = `54.50 for rest of fiscal 2013
**Includes`568crore from Lodestone
Business Highlights
- The company won 8 large outsourcing deals amounting to US$ 731 Mn of total contract value
- Our offerings in the Products and Platforms space continue to see good momentum. This quarter we had 14 wins across industries and geographies. Infosys products and platforms (excluding Finacleâ„¢) are now adopted by more than 70 global clients.
- A Blue Cross Blue Shield Plan selected us as a strategic partner to provide enterprise-wide testing services and establish a Test CoE within its IT organization, aimed at creating testing processes and frameworks to support the company's ongoing transformation due to US healthcare reform. Another Blue Cross Blue Shield Plan is leveraging Infosys iTransformâ„¢ product and services to help its ICD-10 migration, mandated by the U.S. federal government.
- Our focus on Cloud as a new growth area continues to yield results and the Cloud business currently has more than 190 engagements and 3,500 experts. Over the last quarter, we won more than 15 engagements across Cloud services, Big Data and Security. Our vision of being a Cloud Ecosystem Integrator has gained increasing acceptance with clients and we are working with more than 30 partners to help clients create and manage their unified hybrid cloud environments.
- During the third quarter, Infosys applied for seven patent applications in India and the U.S. With this, it has 525 patent applications in India, the U.S. and other jurisdictions, and has been granted 71 patents by the United States Patent and Trademark Office and two patents by the Luxembourg patent office.